Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with non-resectable lung cancer

• Published in: Cancer Immunology Immunotherapy Vol. 33; no. 2; pp. 121 - 127
• Main Authors: Vibe-Petersen, J, Tvede, N, Diamant, M, Kjerulff, A A, Sørensen, H R, Andersen, V
• Format: Journal Article
• Language: English
• Published: Germany Springer-Verlag 01.03.1991
• Subjects: Aged; Antigens, CD - analysis; Antigens, Differentiation, T-Lymphocyte - analysis; CD8 Antigens; Cross-Sectional Studies; Cytokines - analysis; Female; Humans; Longitudinal Studies; Lung Neoplasms - immunology; Middle Aged; Original; Receptors, Interleukin-2 - blood
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/BF01742540

In a preliminary longitudinal study two women with histologically verified adenocarcinoma of the lung, without simultaneous infectious or inflammatory conditions, were seen every 2 weeks until death. In one of the patients serum soluble interleukin-2 receptor (sIL-2R) levels rose progressively while the levels for the other patient increased during the second half of the observation period. Serum soluble CD8 antigen (sCD8 Ag) showed a pattern dissimilar to the one for sIL-2R. In a retrospective cross-sectional study circulating levels of sIL-2R and sCD8 Ag were measured before explorative thoracotomy in a total of 65 patients with histologically proven non-resectable carcinoma of the lung. The sIL-2R levels were significantly increased independently of histological subclassification while sCD8 Ag was increased only in patients with small-cell lung cancer. There was no correlation between pre-operative values and length of survival.